ACT-GEN (Adherence And Care Tracking In GENetic Cancer Syndromes)

Starting soon · Not applicable

Conditions studied: ACT-GEN, Genetic Cancer Syndromes

In brief

To help people with high-risk cancer variants to follow cancer surveillance guidelines and lower their risk of developing the disease.

Key facts

Study ID

NCT07565467

Run by

M.D. Anderson Cancer Center

People needed

80

Starts

2026-10-08

Expected to finish

2033-03-01

Last updated by the study team

2026-05-04

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may not qualify if…

• Part 1 exclusion criteria:
• Unwilling or unable to provide consent; or
• Does not have access to a smartphone or is unable to access the application on their phone;
• Part 2 exclusion criteria:
• Unwilling or unable to provide consent;
• No deleterious or pathogenic variant in HBOC genes (BRCA1/2), or Lynch associated genes (MLH1, MSH2, MSH6, PMS2, or EPCAM);
• Does not have access to a smartphone or is unable to access the application on their phone.
• Actively being treated for malignancy with cytotoxic therapy.
• History of gynecologic or breast malignancy; or
• Has previously undergone bilateral salpingo-oophorectomy (for BRCA1/2).
• Participated in Part 1.

Where it is running

• MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.